# Regimen Optimization Study

> **NCT02137239** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 58 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Thymoglobulin
- **DRUG:** Belatacept
- **DRUG:** mycophenolate mofetil(MMF)
- **DRUG:** Corticosteroids
- **DRUG:** Everolimus(EVL)
- **DRUG:** Tacrolimus(TAC)

## Key facts

- **NCT ID:** NCT02137239
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-31
- **Primary completion:** 2019-05-02
- **Final completion:** 2019-05-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137239, "Regimen Optimization Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02137239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*